Good morning, and welcome to INNOVATE Corporation Third Quarter 2021 Earnings Call. During the presentation, all participants will be in listen-only mode. Afterwards we will conduct a question-and-answer session. [Operator Instructions]. As a reminder, today's conference call is being recorded. I would now like to turn the conference over to Anthony Rozmus, Investor Relations for INNOVATE Corporation. Please go ahead.

Good afternoon. Thank you for being with us to review INNOVATE's third quarter 2021 earnings results. We are joined today by Avie Glazer, Chairman of INNOVATE. Wayne Barr, Jr. CEO of INNOVATE, Mike Sena, INNOVATE's, Chief Financial Officer and Rustin Roach, DBM Global's President and CEO. As usual, we have posted our earnings release and our slide presentation on our website at INNOVATECorp.com. We will begin our call with prepared remarks to be followed by Q&A session. This call will also be simulcast and will be archived on our website. Now for some great disclaimers. During the call, management may make certain statements and assumptions which are not historical facts will be forward-looking and are being made pursuant to the Safe Harbor provisions and the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risks, assumptions, uncertainties, and are subject to certain assumptions and risk factors that could cause INNOVATE's actual results to differ materially from these forward-looking statements. The risk factors that could cause these differences are more fully discussed in the cautionary statement that is included in our earnings release, and the slide presentation and further details in our 10K and other filings with the SEC. In addition, the forward-looking statements included in this conference call are only made as of the date of this call and as stated in our SEC reports. INNOVATE disclaim any intent or obligation to update or revise these forward-looking statements except as expressly required by law. Management will also refer to certain non-GAAP financial measures such as adjusted EBITDA. We believe that these measures provide useful supplemental data that while not a substitute for GAAP measures, allow for greater transparency in the review for our financial and operational performance. At this point, it is my pleasure to turn things over to Avie Glazer.

Good afternoon, everyone. And thank you all for joining us. I'm pleased to be speaking to you today on our first earnings call under our company's new name, INNOVATE. INNOVATE embodies vision for our best-in-class assets we believe that each of our segments is primed to unlock significant value. In infrastructure, the Banker Steel acquisition now has been a part of the DBM family for a full quarter. We are encouraged by the expanded footprint we have in the steel erection and fabrication space in the United States. DBM's revenues increased 138% from the prior year quarter, and adjusted EBITDA was up almost 38%. Moving on to Pansend, one of the most exciting developments this quarter came when R2's Glacial Rx, earned its third FDA indication and unique product code. Glacial Rx is now the first and only class to dermal cooling system FDA-cleared for dermabrasion, scar and acne scar revision, and tattoo removal, permanently changing the aesthetics industry. What this means is that Glacial Rx went from being part of one classification among 100s of other devices to be in place and its very own FDA issued product code. And this significant milestone for R2's will help it further penetrate the $22 billion aesthetic dermatology market. We invested an additional $15 million R2 to increase our ownership position, we continue to be excited by the opportunity. And finally in Spectrum, the adjusted EBITDA positive for the fourth consecutive quarter, we are continually expanding our nationwide broadcast station footprint and the businesses position to take advantage of the opportunities lies ahead with the rise of OTA broadcast access in homes across the country. We couldn't be more excited for the future prospects of INNOVATE Corporation. In fact, I'd like to invite everyone to visit our new website, INNOVATECorp.com, and once you're on the site, you can download our latest investor presentation. I think it's a very informative overview of INNOVATE and what we're doing. And with that, I'm pleased to turn the call over to Wayne Barr, Jr. CEO of INNOVATE.

Thank you, Avie, and thank you all for joining us today. For the third quarter, we delivered financial results that were in line with our expectations and reflective of the continued progress of INNOVATE's long-term strategy. We picked up right where we left off in the second quarter and further execution in all of our segments. Our team remains energized by the opportunities that lie ahead, especially with our unique set of assets that are currently growing as shown by our third quarter results and our position to unlock future value for our stockholders for years to come. Turning now to some key accomplishments achieved in the third quarter that in conjunction with our financial results highlight the aforementioned progress made on the execution of our strategy. As previously mentioned on our last earnings call, we completed the disposition of the Insurance segment Continental General Holdings receiving $65 million of cash at closing and the return of approximately $25 million worth of spectrum securities. Also, as mentioned on the last earnings call, we provided an additional $15 million in Series C funding to R2 Technologies to Pansend or Life Sciences segment. We also completed our name change to INNOVATE Corp launched our rebranding efforts and began trading under the ticker VATE on September 20, 2021. We are initiating a new feature on our quarterly calls and I've asked Rustin Roach, President and CEO of our Infrastructure segment DBM Global to join us today and walk you through an update on DBM before returning the call back to me to provide updates on Pansend and Spectrum. Rustin?

Thanks, Wayne. I'm happy to be joining today to speak to you all about the exciting prospects at DBM. The Banker Steel integration is on track and the company has made an immediate impact to DBM already. Our exposure to commercial industrial services and public sector projects positions DBM well for the post-COVID recovery we are seeing take place in the market today. With that DBM's total adjusted backlog was $1.9 billion at quarter end, comprised of $1.05 billion in legacy DBM backlog and $839 million of backlog at Banker Steel. Our current backlog level provides us with great visibility into the potential revenue generation in 2022 and beyond. We continue to keep our pulse on the various federal infrastructure bills as a potential catalysts for our business. We anticipate we would see the impact of potential new projects associated with a bill in the 12 to 18-month period following final passage. In addition to an infrastructure bills direct impacts. We believe the additional infrastructure spending, if focus correctly, we'll add new projects to an already very busy market, which I'm optimistic will continue to relax the downward pressure on margins we've experienced over the past year. We continue to see point of sale margins improving on new bids. The larger more complex projects have a bit higher margins than the smaller less complex ones. Obviously, this will all be a net positive for DBM. While there remains optimism in the construction industry, we also acknowledge various challenges in both the supply chain with steel prices continuing to rise, as well as in the labor market for our business. While these issues are there, we've continued to find successes in our operational efficiencies and business development efforts as shown by the very large adjusted backlog number of $1.9 billion. We'll continue to monitor both of these elements and the potential impacts to our businesses as we look forward to 2022. Thank you for the time today, and I'll now turn this back over to Wayne.

Thanks Rustin. Now turning to Life Sciences, we are encouraged by the recent developments in our Pansend business. As we explained last quarter, we invested an additional $15 million in R2, if it is using to expand its corporate footprint, accelerate U.S. commercialization of Glacial Rx, field global growth and fund further innovation in product development. The infusion of capital will further support R2 prospects, especially with Glacial Rx receiving its third FDA indication and unique product code. This is a major milestone for R2 in the quarter on the heels of the commercial rollout of its first product earlier in the year. R2 did decide to delay the Chinese launch of the Glacial Spa product, which has been impacted by global supply chain issues. The Glacial Spa and Glacial Rx devices have certain components in common, and at least one of which has been affected by the tightening supply chain. Given the momentum in ample inventory for the Glacial Rx product, R2 made what we believe was a prudent decision to allocate a greater portion of the shared components to satisfy the commercial demand for R2's Glacial Rx product in the United States, rather than using such components in the Glacial Spa device, resulting in the decision to delay the launch. At MediBeacon, the company remains in dialogue with the FDA regarding the commencement of its U.S. pivotal study. MediBeacon hopes to begin that study in the fourth quarter, although there is a possibility that it may be pushed into the first quarter of next year. We are closely monitoring the situation and regardless of a potential delay are very excited about the opportunities we see at MediBeacon. We are happy with the momentum we continue to see at Pansend. We couldn't be more excited about the progress made…

Thanks, Wayne. I'll first review our financial performance, and then I'll walk you through the key changes to our capital structure to help you bridge the quarter and the key transactions that have taken place during the quarter. Consolidated total revenue for the third quarter of 2021 was $394.8 million, an increase of 131.6% compared to $170.5 million in the prior-year period. The increase was driven by our infrastructure segment driven by the contribution from Banker Steel as well as from higher revenues across DBM service offerings attributable to timing of project work under execution and backlog mix. Net loss attributable to common and participating preferred stockholders for the third quarter of 2021 was $213 million, or $2.75 per share, compared to a net loss of $17.7 million or $0.37 per share in the prior-year period. The loss is primarily driven by the loss on the sale of the insurance company in the quarter. While the cash flow restrictions discussed on previous calls changed our risk versus reward outlook on the insurance company. I wanted to spend a couple of minutes to discuss the U.S. GAAP loss recognition on the sale. The loss at the insurance company is reflective of the excess book value of a purchase price. Insurance companies value is typically based on a multiple of the statutory capital. The multiple will vary depending on the type of policies and innovates insurance company consisted primarily of long-term care policies. Long-term care books and business typically trade at a discount to the surplus, this reflects the inherent uncertainty and risk associated with the estimates utilized to determine the insurance reserves to fulfill the long-term care insurance policy obligations. Total adjusted EBITDA, which excludes discontinued operations was $14.3 million in the third quarter of 2021. An increase from adjusted EBITDA…

All right, thank you very much. [Operator Instructions] And nobody in the queue at the moment. [Operator Instructions] And our first question comes from the line of Nitin Sacheti with Papyrus. Please go ahead.

Hi, guys. Nice quarter. Thanks for all the color on the DBM too. So just curious if you could talk about the Continental Insurance sale, and sort of anything on the balance sheet or anything that was sort of a Holdco guarantee that might be gone, that kind of strengthens the overall business now?

Yes, thanks, Nitin. So yes, there's no guarantee. All obligations or commitments that we may have had prior to the sale are now gone. So there's nothing legacy that hangs over. Of course, as far as guarantee, we do have our preferred shares that you'll see on the balance sheet that I just mentioned, that the insurance company holds both the INNOVATE Series A3 and A4 and the DBMI prep that I mentioned.

Okay, thanks.

All right, thank you very much. We have no further questions in the queue at the moment. I'll turn the call back to Wayne Barr for any closing comments.

Great, thank you, Eric. I'd like to thank everybody for participating this afternoon in the earnings call and we look forward to getting back in front of you next quarter. Have a nice day.

That does conclude the conference call for today. We thank you for your participation and you may now disconnect your lines.